Ruth du Moulin
Corporate Officer/Principal chez FORMA THERAPEUTICS HOLDINGS, INC.
Profil
Ruth du Moulin is currently the Vice President-Medical Affairs at Forma Therapeutics Holdings, Inc. She previously worked as the SVP-Medical Affairs & Head-Medical Communications at Millennium Pharmaceuticals, Inc. and as the Vice President-Medical Affairs at ARIAD Pharmaceuticals, Inc. Ms. du Moulin earned a doctorate degree from the National University of Ireland Galway.
Postes actifs de Ruth du Moulin
| Sociétés | Poste | Début |
|---|---|---|
| FORMA THERAPEUTICS HOLDINGS, INC. | Corporate Officer/Principal | 16/09/2020 |
Anciens postes connus de Ruth du Moulin
| Sociétés | Poste | Fin |
|---|---|---|
| ARIAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Formation de Ruth du Moulin
| National University of Ireland Galway | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA. | Health Technology |
Forma Therapeutics Holdings, Inc.
 Forma Therapeutics Holdings, Inc. Pharmaceuticals: MajorHealth Technology Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. engages in the research, development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA. | Health Technology |
